PrEP Biopharm

PrEP Biopharm is a development-stage Biopharmaceutical Company

seeking to create a new paradigm for addressing upper respiratory tract infections.

The unmet medical need:

Upper respiratory viral infections continue to have a significant impact on lives across the world.  In any given year, the average American adult gets 2-3 colds, while children get even more1, and 5-20% of the US population gets infected with the flu2.  This equates to more than 500 million upper respiratory viral infections (URVIs), hundreds of millions of doctor visits, and several hundred thousand deaths3.

Because URVIs affect so many people, the economic costs are significant.  In the US alone, more than $27 billion is spent each year on direct medical expenses related to URVIs, plus an additional $100 billion in indirect costs related to absenteeism and premature deaths6,7,8.

URVIs can be broken down into influenza and non-influenza illnesses.  For influenza, there are available vaccines that can help to prevent infection or minimize symptom severity, however the efficacy of these vaccines is highly dependent upon how well the viruses selected match the viruses circulating that season.  In a year with a good influenza vaccine match, overall efficacy can reach 60%4, but if the match is poor, it results in much lower efficacy.  In 2014, for example, the CDC estimated that the overall efficacy of the influenza vaccine was only 23%, which led to 45% more influenza-related hospitalizations than the previous all-time high5.

There are also several approved antiviral treatments for influenza, however they are only effective in reducing symptom severity/duration and in preventing flu complications, such as pneumonia10.

For non-influenza illnesses, which represent approximately 85% of all URVIs11, there are no available antiviral treatments or vaccines.

  1. 1 National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, February 2016.
  2. 2 “Seasonal Influenza” CDC, July 2011
  3. 3 Fendrick, A.M., Monto, A.S., Nightengale, B., Sarnes, M. The economic burden of non-influenza- related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163:487–494.
  4. 4 www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm
  5. 5 www.cdc.gov/flu/about/season/flu-season-2014-2015.htm
  6. 6 Bertino, Joseph. Cost Burden of Viral Respiratory Infections: Issues for Formulary Decision Makers. The American Journal of Medicine 2002 volume 112 (6A): 42S-49S
  7. 7 Fendrick et. al. The Economic Burden of Non–Influenza-Related Viral Respiratory Tract Infection in the United States, Arch Intern Med. 2003;163(4):487-494
  8. 8 Molinari, NA, Ortega-sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086-96.
  9. 9 Archives of Internal Medicine, Feb. 24, 2003. News release, University of Michigan, Ann Arbor
  10. 10 Relenza and Tamiflu Package Inserts
  11. 11 Treanor JJ et al. Viral infections. In: Murray JF, et al (eds) Textbook of Respiratory Medicine, 3rd edn. Philadelphia, PA: 2000